Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
9 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to MetaVia Inc.’s names, not what it holds today.
Patents granted
9
9 utility, 1976 to Dec 31, 2025
Granted in 2025
1
in the last year the record reads
Applications published
22
since 2001, to Dec 31, 2025
Names they are printed under
5
a former name, a subsidiary
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals1
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
Gemphire Therapeutics Inc. a former name
named as the applicant on its applications, in US
11 publishedNeuroBo Pharmaceuticals, Inc. a former name
US, as the owner printed on each patent
2 publishedGemphire Therapeutics Inc. a former name
US, as the owner printed on each patent
2 publishedNeuroBo Pharmaceuticals, Inc. a former name
named as the applicant on its applications, in US
6 publishedNeuroBo Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Dec 23, 2025 | 12,503,422 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | Organic fine chemistry | NeuroBo Pharmaceuticals, Inc. |
| Mar 16, 2021 | 10,946,053 | Composition containing mixed extract of mulberry and Poria cocos bark for preventing, improving or treating neurodegenerative disorders | Pharmaceuticals | NeuroBo Pharmaceuticals, Inc. |
| Dec 15, 2020 | 10,864,238 | Composition containing Poria cocos peel extract for treating neurodegenerative disorders | Pharmaceuticals | NeuroBo Pharmaceuticals, Inc. |
| Jul 14, 2020 | 10,709,678 | Methods of reducing risk of cardiovascular disease | Pharmaceuticals | NeuroBo Pharmaceuticals, Inc. |
| Mar 17, 2020 | 10,588,927 | Composition containing mixed extract of mulberry and Poria cocos peel | Pharmaceuticals | NeuroBo Pharmaceuticals, Inc. |
| Oct 22, 2019 | 10,449,154 | Treatment of NASH with Gemcabene | Pharmaceuticals | Gemphire Therapeutics Inc. |
| Mar 12, 2019 | 10,227,285 | Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers | Organic fine chemistry | Gemphire Therapeutics Inc. |
| Jul 24, 2018 | 10,028,926 | Methods of reducing risk of cardiovascular disease | Pharmaceuticals | Gemphire Therapeutics Inc. |
| Dec 26, 2017 | 9,849,104 | Treatment of NASH with gemcabene | Pharmaceuticals | Gemphire Therapeutics Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Dec 22, 2022 | 2022/0402854 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKENE ETHERS | Organic fine chemistry | NeuroBo Pharmaceuticals, Inc. |
| Oct 20, 2022 | 2022/0332672 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | Organic fine chemistry | NeuroBo Pharmaceuticals, Inc. · patent 12,503,422 granted from it |
| Feb 3, 2022 | 2022/0031642 | Niclosamide Formulations and Methods of Use | Pharmaceuticals | NeuroBo Pharmaceuticals, Inc. |
| Nov 11, 2021 | 2021/0346324 | Niclosamide Formulations and Methods of Use | Pharmaceuticals | NeuroBo Therapeutics, Inc. |
| Sep 16, 2021 | 2021/0283206 | COMPOSITION CONTAINING MIXED EXTRACT OF MULBERRY AND PORIA COCOS BARK | Pharmaceuticals | NeuroBo Pharmaceuticals, Inc. |
| May 6, 2021 | 2021/0128656 | COMPOSITION CONTAINING PORIA COCOS PEEL EXTRACT FOR TREATING NEURODEGENERATIVE DISORDERS | Pharmaceuticals | NeuroBo Pharmaceuticals, Inc. |
| Sep 17, 2020 | 2020/0289594 | COMPOSITION CONTAINING MIXED EXTRACT OF MULBERRY AND PORIA COCOS BARK FOR PREVENTING, IMPROVING OR TREATING NEURODEGENERATIVE DISORDERS | Pharmaceuticals | NeuroBo Pharmaceuticals, Inc. · patent 10,946,053 granted from it |
| Aug 13, 2020 | 2020/0253877 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | Pharmaceuticals | NeuroBo Pharmaceuticals, Inc. |
| May 14, 2020 | 2020/0148617 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | Organic fine chemistry | Gemphire Therapeutics Inc. |
| Feb 13, 2020 | 2020/0048181 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | Organic fine chemistry | Gemphire Therapeutics Inc. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.